NEW YORK (GenomeWeb News) – Shares of Qiagen rose around 6 percent in Friday trade on the Nasdaq after rumors circulated in Europe that French drugmaker Sanofi-Aventis was mulling a €14.50 ($20.29) per share bid to acquire the firm.

Neither firm would comment on the rumors.

The rumored acquisition price represents a 26 percent premium over Qiagen's Thursday closing price of $16.05. In Friday afternoon trade, Qiagen's shares were up 6 percent at $17.01.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.